A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

NCT03946670 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

127

Enrollment

INDUSTRY

Sponsor class

Stopped In December 2023, Novartis decided to terminate the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) studies failed to meet their primary objectives. The termination was not due to safety concerns.

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: MBG453
DRUG: Placebo
DRUG: Hypomethylating agents

Sponsor

Novartis Pharmaceuticals